Navigation Links
OmegaGenesis Announces Angiogenesis Application Collaboration
Date:12/15/2008

development process and marketplace applications," said Oostur Raza.

It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to greatly advance the treatment of primary diseases potentially affecting hundreds of millions globally.

OmegaGenesis through its collaboration with Mayo Clinic has retained exclusive license to further test Angiogenesis characteristics of these nano rods and develop products. The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.

In addition to licensing technology and patents to OmegaGenesis, Mayo Clinic and OmegaGenesis scientists will cooperate in conducting lab tests.

About OmegaGenesis

OmegaGenesis, Inc. is a venture funded bio-technology company based in Gilroy, California and Rochester, Minnesota. OmegaGenesis was founded in 2008 to bring Mayo Clinic core research and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical applications ranging from cancer and malignancies treatments to common wound healing and tissue reactivation.

The Company was founded to discover and produce suitable nano-materials to manage human body functions at a nano scale -- the cell and sub-cell level -- accelerating cellular-based biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at sub-cell level in a non-intrusive manner instead of treating the disease at the organ or tissue level.

Our mission emphasizes collaborative research in partnership with leading medical centers, rapid product design, development, and validation. OmegaGenesis collaborates with strategic academic and corpor
'/>"/>

SOURCE OmegaGenesis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
2. Banyan Biomarkers Announces Issuance of U.S. Patent for Biomarkers for Traumatic Injury
3. Osteotech Announces Stock Repurchase Program
4. Martek Announces Fourth Quarter and FY 2008 Financial Results
5. Helix BioPharma Announces Q1 2009 Financial Results
6. Neogen Announces New Share Repurchase Program
7. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
8. Oridion Announces Significant Medical Research to be Presented at AARC Congress
9. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
10. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
11. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... 11 Ambit Biosciences Corporation announced today the ... D. Anderson Cancer Center of the first patient in ... E fficacy) Phase 2 pivotal trial in ... AC220 is a novel, orally available, potent and ... a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE ...
(Date:12/11/2009)... PA December 11, 2009 -- Esco announces the opening of a ... serve as a technical service, training and logistics center to support ... of New Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... the opening of a NEW 2nd North American facility in Marietta, ...
(Date:12/10/2009)... the economy and markets exhibiting continued signs of growth, ... equity research provider, will seek to educate investors on ... cap market at the firm,s First 2010 Micro ... Grand Hyatt Hotel in New York, NY. ... much of Wall Street, but the well-informed investor has ...
(Date:12/10/2009)... CORALVILLE, Iowa, Dec. 10 Vivakor, ... that it has entered into an exclusive, ... specialist, Regeneca International, Inc. ( www.regeneca.com ). ... distribution rights to a new cutting-edge nutraceutical ... the development of future formulations by Vivakor ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... its revolutionary Trusted LASIK Eye Surgeons directory service ... . What sets the Trusted LASIK Surgeons directory ... only the best LASIK Surgeons in the United ... LASIK Surgeon Dr. R. Wayne Bowman, are screened ...
... Therapeutics, Inc., a,biotechnology company focused on the ... poorly controlled inflammation, announced today,the successful completion ... and pharmacokinetics study of LT-NS001, the Company,s ... from December, 2007,through July, 2008 in normal ...
... LifeVantage Corporation,(OTC Bulletin Board: LFVN), the maker of Protandim(R), ... of aging, today announced,that the company,s President & CEO, ... 3-Minute Press Show., The interview gives viewers an ... latest press release., To view ...
Other Biology Technology:Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 2Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 3Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 4Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 5Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 6Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2[video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2
(Date:12/11/2009)... children understand that green plants photosynthesize, absorb carbon ... profound global-scale effects that photosynthesis has had on ... the origins and evolution of photosynthesis is Jeffrey ... of Life Sciences. , Oxygen, one of the ... and their descendants (including algae and higher plants), ...
(Date:12/11/2009)... nearly two decades, Ivy Pike, an associate professor of ... ethnic groups in rural northern Kenya to understand how ... living there. , The results of her and her ... in three pastoralist communities of northern Kenya: A conceptual ... Social Science and Medicine , in collaboration with ...
(Date:12/11/2009)... December 11, 2009 Keystone Symposia on ... the appointment of five new Keystone Symposia Fellows ... enables five talented early-career life scientists (postdoctoral trainees ... program development process for one year. Fellows are ... as a commitment to promoting diversity in the ...
Breaking Biology News(10 mins):'Extreme' genes shed light on origins of photosynthesis 2'Extreme' genes shed light on origins of photosynthesis 3UA-led study grapples with health effects of low-intensity warfare 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Reportlinker Adds World Botulinum Toxin Market Report 56773 1Reportlinker Adds World Botulinum Toxin Market Report 56773 2Reportlinker Adds World Botulinum Toxin Market Report 56773 3Reportlinker Adds World Botulinum Toxin Market Report 56773 4Reportlinker Adds World Botulinum Toxin Market Report 56773 5Reportlinker Adds World Botulinum Toxin Market Report 56773 6Reportlinker Adds World Botulinum Toxin Market Report 56773 7Reportlinker Adds World Botulinum Toxin Market Report 56773 8Reportlinker Adds World Botulinum Toxin Market Report 56773 9Reportlinker Adds World Botulinum Toxin Market Report 56773 10Reportlinker Adds World Botulinum Toxin Market Report 56773 11Reportlinker Adds World Botulinum Toxin Market Report 56773 12Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 1Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 2Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 3Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 4Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 5Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 6Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 7Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 8Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 9Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 10Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 11Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 12Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 13Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 14Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 15Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 16Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 17Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 18Groups are key to good health 56765 1Groups are key to good health 56765 2Groups are key to good health 56765 3
... with lead partner Women & Infants Hospital of Rhode ... expand its participation in the National Children,s Study, a ... The National Institute of Child Health and Human Development ... the National Institutes of Health, announced the award today. ...
... A UC Riverside-led team of biomedical scientists has found ... treat acne and skin infections, can be used to treat ... of mental impairment and the most common cause of autism. ... the approval of a new clinical trial in Toronto, Canada, ...
... his State of the Union Address on January 23, 2007, ... oil imports, "We must increase the supply of alternative fuels, ... gallons of renewable and alternative fuels in 2017." , ... in the 2008 Farm Bill and a $45 subsidy per ...
Other Biology News:Brown University and Women & Infants Hospital expand national children's study to Bristol County 2Brown University and Women & Infants Hospital expand national children's study to Bristol County 3Brown University and Women & Infants Hospital expand national children's study to Bristol County 4UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 2UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 3Mandate for biofuels production requires science-based policy and global perspective 2
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
PKA Sampler Kit 10 mu g each...
DNA Repair Sampler Kit 10g each...
Biology Products: